Dr. Xiang Li, President of BioDuro-Sundia Drug Discovery, explains: “At BioDuro-Sundia, we are fully invested in our clientele and pro-actively planning ahead to meet their needs. A few highlights of this expansion include:

• Discovery Biology department:
  • Enlarged HCS capability
  • Developed more than 180 new biochemical and cell assays
• Pharmacology department added 15+ new disease models
• Oncology department:
  • Added 40+ CDX models
  • Increased IVIS based real-time metastasis and drug distribution analyses
• Biologics department initiated a VHH library based on:
  • Alpaca immunity, ADC, high-throughput antibody expression, affinity detection and physical and chemical characterization services
• DMPK department added many in-vivo and in-vitro detection services.

All together, we substantially enhanced our capabilities and capacity to provide better services to our customers. We’re committed to offering both our pharma and biotech partners worldwide advanced, high-quality technical solutions for new drug discovery.”

Dr. Kent Payne, BioDuro-Sundia’s CEO, stated: “Our Discovery Team has advanced countless candidate compounds to the clinic around the world. These new expansions position us for continued growth as part of our commitment to accelerate client projects to the clinic.”

BioDuro-Sundia’s Drug Discovery platform provides end-to-end services from hit identification to lead optimization and candidate selection/profiling. Some notable technology platforms developed at BioDuro-Sundia include PROTAC, Fragment-based drug discovery (FBDD), DNA-encoded library (DEL), Nanobody, NASH models etc.